Viatris Reveals Generic Rybelsus Candidate As Part Of Continued Complex Push
Eight Complex Programs Are At Various Stages Of Development
Recently-formed Viatris is looking to build on the success of several high-margin complex generics launches, including versions of Advair and Copaxone, by developing further candidates, including rivals to Novo Nordisk’s Rybelsus (semaglutide) and Victoza (liraglutide).
You may also be interested in...
As CEO Michael Goettler provides an update on the progress made by Viatris in its first year as a combined company, he also offers Generics Bulletin hints as to the detailed strategy that will be unveiled at the firm’s upcoming investor day and explains how biosimilars – including interchangeable Semglee (insulin glargine) – and complex generics are important components of the firm’s future growth plans.
The latest tranche of product-specific guidances for generic development has been published by the US FDA, following two released in March and May this year.
Viatris has reiterated the strength of its biosimilars and complex generics pipeline, highlighting opportunities including biosimilar Eylea, Botox and once-a-month Copaxone.